EP0563177A1 - Administration orale d'interferon alpha pour traiter les tumeurs malignes des poumons - Google Patents

Administration orale d'interferon alpha pour traiter les tumeurs malignes des poumons

Info

Publication number
EP0563177A1
EP0563177A1 EP92901697A EP92901697A EP0563177A1 EP 0563177 A1 EP0563177 A1 EP 0563177A1 EP 92901697 A EP92901697 A EP 92901697A EP 92901697 A EP92901697 A EP 92901697A EP 0563177 A1 EP0563177 A1 EP 0563177A1
Authority
EP
European Patent Office
Prior art keywords
treating
alpha interferon
preventing
interferon
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92901697A
Other languages
German (de)
English (en)
Inventor
Robert J. Spiegel
Francis M. Cuss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of EP0563177A1 publication Critical patent/EP0563177A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • This invention relates to pharmaceutical compositions comprising human alpha interferon (hIFN- ⁇ ) as an active ingredient to treat lung malignancies in mammals.
  • the invention also relates to the use of hIFN- ⁇ for making medicaments for treating lung malignancies in mammals as well as to methods of treating lung malignancies, generally referred to as lung cancer, by administering by oral inhalation to a mammal in need of such treating an amount of human alpha in recombinant DNA human alpha interferon (rhIFN- ⁇ ) effective for such treating.
  • Human alpha interferon (hlFN- ⁇ ) is a naturally occurring mixture of at least eleven compounds including those designated alpha-1 interferon and alpha-2 interferon.
  • alpha interferon species or components are known and are usually designated by a numeral and letter after the Greek letter alpha.
  • Human alpha-1 interferon is one species contemplated for use in this invention as are the species designated human alpha- '2 interferons.
  • recombinant DNA human alpha-2 interferons are designated Interferon Alpha-2a, which can be made as disclosed in Rubenstein, Biochem. Biophys. Acta (1982), 695, 5-16, and Interferon Alfa-2b.
  • Interferon Alfa-2b is the preferred species for use in this invention and is a recombinant DNA human alpha interferon (hereinafter ThlFN- ⁇ *) .
  • ThlFN- ⁇ * a recombinant DNA human alpha interferon
  • Another suitable rhIFN- ⁇ included in the acope of this invention is recombinant DNA human interferon alpha-2a.
  • Human interferon alfa-2b can be produced in bacteria and other microorganisms using recombinant DNA techniques including those disclosed in Nagata et al. Nature, (1980) 284, 316-329; European Patent 32,134 and U.S. Patent No. 4,289,690.
  • Various alpha interferon species are disclosed in U.S. patent 4,503,035.
  • IFN- ⁇ intralesionally to treat condylomate acuminata.
  • Several groups of investigators have documented that parenterally administered IFN- ⁇ does not accumulate in the nasopharyngeal, oropharyngeal, or airway mucosa or in the lung parenchyma in sufficient concentrations or for long enough time periods to be effective against respiratory virus infections.
  • hlFN- ⁇ * ⁇ non- recombinant human leukocyte alpha-interferon
  • hlFN- ⁇ * ⁇ non- recombinant human leukocyte alpha-interferon
  • Nebulized hlFN- ⁇ inhibits viral replication in mice (Please give Reference) .
  • the instillation of hlFN- ⁇ into the bronchi of perfused rabbit lungs has resulted in measurable serum concentrations [V. Bocci et al., Antiviral Res. (1984) Vol. 4, 211-220].
  • interferon- ⁇ (hlFN- ⁇ ) given both intranasally and intraorally at a dose of 700- 1600 units/day was effective in the treatment of influenza, respiratory syncytial viral bronchiolitis, and asthmatic bronchitis (Jia-xiong, et al, Chin Med J. 100:162-166, 1987).
  • hlFN- ⁇ has been inhaled by patients with advanced non-small cell lung cancer at doses up to 120 million International Units ("IU") .
  • IU International Units
  • Kinnula et al. discloses in the J. Interferon Res. (1989), Vol 9, 419-23 that inhaled hlFN- ⁇ resulted in serum concentration and side effects (e.g. fever, headache, influenza-like symptoms and nausea) similar to those disclosed after systemic hlFN- ⁇ administration as well as reversible airflow obstruction but no activity against the lung cancer was observed.
  • Inhaled hlFN- ⁇ has also been administered to patients suffering from bronchoalveolar carcinoma but no activity on the bronchoalveolar carcinoma has been demonstrated [V. Kinnula et al. J. Interferon Res, (1988) Vol 8, Suppl. 1 pll5]
  • the present invention provides a pharmaceutical composition for treating or preventing a lung malignancy in a mammal which composition comprises an effective amount of recombinant DNA human alpha interferon.
  • the present invention also provides a use of recombinant DNA human alpha interferon for the manufacture of a medicament for treating or preventing a lung malignancy in a mammal.
  • This invention also provides a method of treating a lung malignancy in a mammal afflicted with such malignancy which comprises administering via oral inhalation to such a mammal an amount of recombinant human DNA alpha interferon effective for such treating.
  • This invention also provides a method of preventing a lung malignancy in a mammal susceptible to lung malignany - e.g. heavy smokers of any tobacco products especially cigars and cigarettes, which comprises administering via oral inhalation to such a mammal ' an amount of recombinant DNA human alpha interferon effective for such preventing.
  • lung malignancy means at least one of squamous cell carcinoma, large cell carcinoma, small cell carcinoma, alveolar cell carcinoma, bronchoalveolar carcinoma, adenocarcinoma, bronchogenic carcinoma-in-situ, metastatic carcinoma, or sarcoma from primary tumors outside the lung or airways.
  • the effectiveness of the interferon therapy of this invention can be shown clinically in mammals, e.g. human beings afflicted with a lung malignancy or suspectible to a lung malignancy due to the smoking tobacco products, especially cigarettes and/or cigars using patients with the following entry criteria:
  • the recombinant DNA human alpha interferon (rhIFN- ⁇ ) administered via oral inhalation in accordance with this invention may be used as monotherapy or as adjunctive therapy with other treatments e.g., chemotherapy or immunotherapy to treat lung malignancy and prevent, inhibit and/or cure the pulmonary metastatic spread of one or more of the types of lung malignancies listed hereinabove.
  • treatments e.g., chemotherapy or immunotherapy to treat lung malignancy and prevent, inhibit and/or cure the pulmonary metastatic spread of one or more of the types of lung malignancies listed hereinabove.
  • the list of conventional chemotherapeutic agents useful in combination with alpha interferon is disclosed by S. Wadler et al in Cancer Research (1990), Vol 50 pp 5472-3486.
  • the recombinant DNA human alpha interferon (“rhlFN- ⁇ *) is administered by oral inhalation in accordance with this invention as a pharmaceutical composition containing rhIFN- ⁇ which may be dissolved or dispersed in a pharmaceutically acceptable carrier suitable for use in a nebulizer and/or a metered dose inhaler.
  • pharmaceutically acceptable carriers include, for example, water, saline, ethanol and the like which form a rhIFN-o solution or suspension suitable for administration via oral inhalation in accordance with this invention.
  • the rhIFN- ⁇ pharmaceutical composition useful in this invention may also contain minor amounts of non-toxic auxiliary substances such as melting agents, emulsifying agents, preservatives, stabilizers, and pH buffering agents.
  • auxiliary substances such as melting agents, emulsifying agents, preservatives, stabilizers, and pH buffering agents.
  • the preparation of these pharmaceutical compositions is well known to those skilled in the art; see for example Remington's Pharmaceutical Sciences Mack Publishing Co., Easton PA 15th Edition (1975) .
  • a preferred rhIFN- ⁇ pharmaceutical composition for use in accordance with this invention is the Intron® A brand of interferon available as a solution from Schering-Plough Corporation, Kenilworth, New.Jersey.
  • This commercially available Intron A rhIFN- ⁇ composition contains glycine, di- and mono- basic sodium phosphate as a buffer and serum albumin.
  • Other preferred rhIFN- ⁇ pharmaceutical compositions include any sterile isotonic aqueous solution, e.g. physicological phosphate-buffered saline at pH 7.3 which may also contain pharmaceutically acceptable non-toxic auxiliary agents such as stabilizers and/or a surfactants and the desired amount of rhIFN- ⁇ .
  • the concentration of rhIFN- ⁇ in the pharmaceutical composition may be adjusted by dilution with 0.9% saline solution before administration via oral inhalation.
  • nebulizers and metered dose inhalers are well known. See for example Remington, ibid, at chapter 99, pages 1910-1912.
  • Useful nebulizers include the Spira Electro 4 nebulizer, manufactured by Hameenlinman Ty ⁇ leskus, Hameenlinna, Finland, whose use is disclosed by Kinnula et al. in the J. of Interferon Research (1989) Vol. 9 at p420.
  • Useful metered dose inhalers as well as drug delivery systems that help deliver oral aerosolized medications from metered dose inhalers to the lungs include INHAL-AID and INSPIREASE drug delivery systems available from Schering-Plough Corporation, Kenilworth, New Jersey, U.S.A, for as well as those disclosed in the Physicians Desk Reference, 1990 Edition, for use with bronchodilators.
  • the output of the nebulizer or metered dose inhaler for use in this invention should consistently and reliably produce particles and/or droplets having a mass median aerodynamic diameter (M.M.A.D.) above about 0.5 microns, preferably having a M.M.A.D.
  • inhaled particles and/or droplets containing rhIFN- ⁇ having a M.M.A.D in the range of above about 0.5 to less than about 8 microns are suitable for deposition on the peripheral airways and lungs and thus maximize the beneficial effects of inhaled rhIFN- ⁇ .
  • Droplets and particles having a M.M.A.D. greater than 8 microns become impacted in the upper airways; and those having a M.M.A.D. less than about 0.5 microns tend to behave like a gas and are exhaled.
  • droplets and/or particles of rhIFN- ⁇ having the preferred M.M.A.D. have a high surface energy and tend to agglomerate.
  • a surfactant preferably a non-volatile liquid soluble in the propellant used in nebulizers or metered dose inhalers is desirable to lessen such agglomeration.
  • the effective amount of rhIFN- ⁇ for treating and/or preventing a lung malignancy in accordance with this invention is a dosage range of rhIFN- ⁇ of about l x 10 6 international units (IU) to about 1 x 10 11 IU, preferably about 1 x 10 6 IU to about 5 x 10 10 IU, and more preferably about 1 x 10 6 IU to about 2 x 10 10 IU.
  • the rhINF- ⁇ maybe administered daily in single or divided doses.
  • the amount of rhIFN- ⁇ administered and the treatment regimen used will, of course, be dependent on the age, sex and medical history of the patent being treated, the severity of the specific lung malignancy and the tolerance of patient to the treatment regimen as evidenced by local toxicity (e.g. nasal irritation and/or bleeding) and by systemic side effects (e.g. fever, malaire pan ⁇ ytopenia, CNS depression, gastrointestinal irritation and elevated liver enzymes) .
  • local toxicity e.g. nasal irritation and/or bleeding
  • systemic side effects e.g. fever, malaire pan ⁇ ytopenia, CNS depression, gastrointestinal irritation and elevated liver enzymes
  • Study Design Prior to ' enrollment, all patients are throughly examined and their disease clinically staged using chest x-rays, computerized tomography, EKG, hematologic and blood chemistries. Clotting studies including total fibrinogen determination, PTT, PT, TT, and fibrin degradation products are conducted. Karnofsky performance status, pulmonary function including peak expiratory flow (PEF) , forced expiratory volume in one second (FEV ⁇ ) , and forced vital capacity (FVC) are measured. Subjective and objective symptoms including the number and severity of coughing bouts, shortness of breath, pain and coughing-up of blood as well as body temperature, blood pressure, and heart rate are measured.
  • PEF peak expiratory flow
  • FEV ⁇ forced expiratory volume in one second
  • FVC forced vital capacity
  • Serum rhIFN- ⁇ concentrations are determined by use of commercially available immunoradiometric assays (Abbott Diagnotic ' s and Centocor, respectively) or by vesicular stomatitis virus (VSV) plaque reduction in HEp2 cultures. Measurement are performed before inhalation and 2hr, 5hr, lOhr, 15hr and 24 hr after inhalation.
  • VSV vesicular stomatitis virus
  • Each patient is vigorously monitored for early signs of toxicity as well as radiographic evidence of clinical effectiveness throughout the treatment course . and on a regular basis thereafter.
  • Methods of evaluation include frequent physician examination, a regular schedule for performance of laboratory procedures including hematologic and serum chemistries pulmonary function and clotting studies.
  • Radiographic studies include chest x-rays and CT scans as appropriate.
  • •Toxicity is graded in accordance with the Work Health Organization's recommendations for grading of acute and subacute toxicity. Performance status is graded from zero to four with complete disability being defined as four.
  • Tumor response is determined by means of serial radiographic studies. Areas of referenced tumors are determined by multiplication of the longest diameter by the greatest perpendicular diameter.
  • Complete response would be then defined as the disappearance of all measurable disease determined by observation separated by at least four weeks with the appearance of no new lesions within the radiation portal.
  • Partial response is a 50% decrease in the referenced tumor mass and stable disease would be defined as a less than 50% decrease in tumor size, or less than 25% increase. A tumor growth larger than 25% is considered progressive disease.
  • Symptoms and objective side effects of rhIFN- ⁇ therapy including changes in body temperature, airflow obstructure and flu-like symptom are also measured.
  • a reduction in tumor growth and/or lung malignancy by administering by oral inhalation rhIFN- ⁇ to patients in need of such administer is expected.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention se rapporte à une composition pharmaceutique servant au traitement ou à la prévention des tumeurs malignes des poumons chez les mammifères et comprenant un interféron alpha humain d'ADN de recombinaison (rhIFN-alpha), à l'utilisation du rhIFN-alpha dans la fabrication d'un médicament servant au traitement ou à la prévention des tumeurs malignes des poumons chez les mammifères, ainsi qu'à un procédé de traitement ou de prévention des tumeurs malignes des poumons chez les mammifères, qui consiste à administrer par inhalation orale à un mammifère atteint d'une tumeur maligne des poumons une quantité efficace de rhIFN-alpha à l'aide d'un ébuliseur ou d'un inhalateur doseur.
EP92901697A 1990-12-14 1991-12-11 Administration orale d'interferon alpha pour traiter les tumeurs malignes des poumons Withdrawn EP0563177A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62824090A 1990-12-14 1990-12-14
US628240 1990-12-14

Publications (1)

Publication Number Publication Date
EP0563177A1 true EP0563177A1 (fr) 1993-10-06

Family

ID=24518070

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92901697A Withdrawn EP0563177A1 (fr) 1990-12-14 1991-12-11 Administration orale d'interferon alpha pour traiter les tumeurs malignes des poumons

Country Status (11)

Country Link
EP (1) EP0563177A1 (fr)
JP (1) JPH06503570A (fr)
AU (1) AU9139091A (fr)
CA (1) CA2098393A1 (fr)
EE (1) EE9400337A (fr)
IE (1) IE914326A1 (fr)
IL (1) IL100332A0 (fr)
MX (1) MX9102512A (fr)
PT (1) PT99784A (fr)
WO (1) WO1992010207A1 (fr)
ZA (1) ZA919769B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9213322D0 (en) * 1992-06-23 1992-08-05 Efamol Holdings Antioxidant compositions
ES2161793T3 (es) * 1994-04-09 2001-12-16 Hoffmann La Roche Proceso para la produccion de alfa-interferona.
AUPN976596A0 (en) * 1996-05-09 1996-05-30 Pharma Pacific Pty Ltd Stimulation of host defence mechanisms
US6207145B1 (en) 1997-05-09 2001-03-27 Pharma Pacific Pty Ltd. Therapeutic applications of high dose interferon
CN1151840C (zh) * 1996-05-09 2004-06-02 太平洋制药控股公司 干扰素在制备用于治疗哺乳动物肿瘤病的药剂中的应用
ATE316792T1 (de) * 1996-05-09 2006-02-15 Pharma Pacific Pty Ltd Stimulierung wirtseigener abwehrmechanismen gegen krebs
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
AU2002330801A1 (en) * 2002-06-20 2004-01-06 Igor Anatolievich Pomytkin Method for oral transmucosal delivery of interferon

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0077063B1 (fr) * 1981-10-13 1988-03-16 Exovir, Inc. Compositions contenant de l'interféron et application de ces compositions dans le traitement des infections herpétiques, lésions prémalignes de la peau, malignités de la peau et psoriasis
AU634511B2 (en) * 1988-12-01 1993-02-25 Schering Corporation Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9210207A1 *

Also Published As

Publication number Publication date
MX9102512A (es) 1992-06-01
IL100332A0 (en) 1992-09-06
EE9400337A (et) 1996-02-15
ZA919769B (en) 1992-09-30
JPH06503570A (ja) 1994-04-21
PT99784A (pt) 1992-12-31
CA2098393A1 (fr) 1992-06-15
IE914326A1 (en) 1992-06-17
WO1992010207A1 (fr) 1992-06-25
AU9139091A (en) 1992-07-08

Similar Documents

Publication Publication Date Title
US5618786A (en) Aerosolization of protein therapeutic agent
CN1094642A (zh) 治疗组合物
EP0563177A1 (fr) Administration orale d'interferon alpha pour traiter les tumeurs malignes des poumons
US5178855A (en) Treatment of luekocyte dysfunction with GM-CSF
JP2704546B2 (ja) Ａｔｌｌ治療用吸入剤
US4806347A (en) Interferon combinations
Podzamczer et al. Low‐dose interferon alpha combined with zidovudine in patients with AIDS‐associated Kaposi's sarcoma
Kinnula et al. Effect of inhaled natural interferon-alpha on diffuse bronchioalveolar carcinoma
JP4721488B2 (ja) 腎細胞ガン処置
WO1992011025A2 (fr) Administration d'interferon-alpha par inhalation orale pour le traitement de l'asthme et de maladies pulmonaires proliferatives non malignes
US5780012A (en) Method for reducing lung afflictions by inhalation of cytokine solutions
US6030609A (en) Method and composition for treating paramyxovirus
JP2759050B2 (ja) 突発性難聴治療用医薬組成物
Douglas et al. A comparative study of two doses of salbutamol nebulized at 4 and 8 litres per minute in patients with chronic asthma
Hockley et al. Fenoterol versus salbutamol nebulization in asthma
JP2001516725A (ja) 慢性Ｃ型肝炎症の処置のためのＩＦＮ−αとアマンタジンの使用
US20240009227A1 (en) Use of a heparin composition in the treatment of viral lung diseases, acute and/or chronic lung diseases by soft mist inhaler or vibration mesh technology nebulizer through inhalation route
JPWO2021211885A5 (fr)
Leventhal et al. Recurrent respiratory papillomatosis
RU1801495C (ru) Способ лечени острой инфекционной деструкции легких
Susskind Inhalation delivery of drugs
Asmar et al. Antiviral therapy: Respiratory infections, chornic hepatitis
Cottoni et al. Recombinant α-2b-interferon in classic Kaposi's sarcoma

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930610

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19931214

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19940625